THE USE OF CEACAM5 PEPTIDES AS AN IMMUNOTHERAPY FOR CROHN’S DISEASE
Crohn’s Disease (CD) is a chronic relapsing/remitting inflammatory disease of the gastrointestinal tract affecting about 800,000 patients in the US and Europe alone with rising incidence rates. In addition to reduced quality of life for CD patients, the chronic inflammation associated with …
A PROTOCOL FOR GENERATION OF FUNCTIONAL MYELOID-DERIVED SUPPRESSOR CELLS FROM EMBRYONIC STEM CELLS AND HEMATOPOIETIC STEM CELLS
To date, a major limiting factor for the use of MDSCs in certain therapies – in pathological settings where deleterious or excessive immune responses need to be avoided or reduced – is the source of MDSCs. Mount Sinai researchers demonstrated efficient in …
HARNESSING THE IMMUNOSUPPRESSIVE CHARACTERISTICS OF MYELOID DERIVED SUPPRESSOR CELLS (MDSC) TO TREAT OR PREVENT AUTOIMMUNE DISEASES AND GRAFT-VERSUS-HOST DISEASE (GVHD)
Emerging evidence suggests that MDSCs have great potential as an immune intervention modality in both transplantation and autoimmune disease settings. Mount Sinai investigators demonstrated their utility in both GVHD and Type 1 Diabetes. Coupled with a suite of other pending patent applications …
NOVEL BROMODOMAIN (BRD4) SMALL MOLECULE INHIBITORS FOR TARGETED TREATMENT OF CANCER
Bromodomain-containing proteins function as chromatin modifiers and mediators of protein-protein interactions, controlling gene expression. BRDs have been functionally implicated in numerous disease processes, including cancer, and small molecule inhibitors have been developed with some advancing to early clinical trials in cancer. BRD4 …
NOVEL METHOD TO SPECIFICALLY INHIBIT CATHEPSIN K COLLAGENOLYTIC ACTIVITY
Bone homeostasis is a complex process and requires a balance between bone formation and resorption. Cathepsin K is a collagenase which is highly expressed in bone resorbing cells and its deficiency leads to pycnodysostosis, a rare disease characterized by a decrease in …